{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-192006","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2022-07-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.775207+00:00","generated_at":"2026-06-24T16:35:53.667064+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Agios appoints Brian Goff as CEO; Jackie Fouse transitions to Chair effective Aug 8, 2022","bullets":["CEO Brian Goff appointed effective Aug 8, 2022; current CEO Jackie Fouse becomes Chair of Board.","Goff receives $775K base salary, 70% target bonus, equity grants: $9M options, $5M PSUs, $2M RSUs.","Goff also gets $250K relocation payment; equity awards vest over 3–4 years under Nasdaq inducement grant.","Fouse's unvested equity continues to vest; she will not receive director equity awards in 2022.","Former chair David Schenkein remains on board as director."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-192006","json":"https://secwatch.observer/filing/0001193125-22-192006.json","markdown":"https://secwatch.observer/filing/0001193125-22-192006.md","text":"https://secwatch.observer/filing/0001193125-22-192006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000119312522192006/0001193125-22-192006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000119312522192006/d267394d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T16:35:53.667064+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04d94265f3","claim":"Jacqualyn A. Fouse changed role as Chair of the Board at AGIOS PHARMACEUTICALS, INC..","evidence_excerpt":"Jacqualyn A. Fouse, Ph.D. will resign from the position of Chief Executive Officer and will assume the role of Chair of the Board of Directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439222/000119312522192006/0001193125-22-192006-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"assume the role of"},{"label":"Role","value":"Chair of the Board"}],"fact_type":"executive_change"},{"claim_id":"d71b2fdb0f","claim":"Brian Goff was appointed as Chief Executive Officer at AGIOS PHARMACEUTICALS, INC..","evidence_excerpt":"the Board appointed Brian Goff as the Company’s Chief Executive Officer and as a member of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439222/000119312522192006/0001193125-22-192006-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}